Objective—To evaluate the safety, with respect to
the development of gastric ulcers and erosions, of
concurrent administration of meloxicam and dexamethasone
for 3 days to healthy dogs.
Animals—20 conditioned purpose-bred research
Procedure—Seven days prior to treatment, dogs
were anesthetized for endoscopic evaluation of the
upper portion of the gastrointestinal tract (ie, the gastric
and duodenal mucosa). Five regions of the gastroduodenal
area were scored by 2 investigators.
Dogs were randomly assigned to 1 of 4 treatment
groups as follows: saline-saline, dexamethasonesaline,
saline-meloxicam, and dexamethasone-meloxicam
groups. On days 1, 2, and 3, dogs received either
dexamethasone or saline (0.9% NaCl) solution injections
SC twice daily. On days 2, 3, and 4, dogs
received either meloxicam or saline solution injections
SC once daily. On day 2, dogs were anesthetized
for a sham surgery (ie, electrostimulation).
On day 5, the gastroduodenal area of each dog was
reevaluated by use of endoscopic evaluation and histologic
examination of biopsy specimens.
Results—The total endoscopic score of the dexamethasone-
meloxicam group was significantly greater
than the scores of the other groups. The dexamethasone-
saline group had a mean cumulative score that
was significantly greater than the saline-meloxicam or
saline-saline groups. Endoscopic scores of the salinemeloxicam
group were not significantly different from
scores of the saline-saline group. No significant differences
in histologic findings were found between
Conclusions and Clinical Relevance—In healthy
dogs, meloxicam appears to be safe with regard to
adverse effects on the gastrointestinal tract.
Concurrent administration of dexamethasone and
meloxicam is more likely to cause gastric erosions
than meloxicam administration alone. (Am J Vet Res 2003;63:1369–1375)
To determine the optimal energy profile for and to assess the feasibility and efficacy of ultrasonographic and laparoscopic guidance for microwave ablation (MWA) of clinically normal canine ovaries.
44 extirpated ovaries from 22 healthy dogs.
In the first of 2 trials, 13 dogs underwent oophorectomy by routine laparotomy. Extirpated ovaries underwent MWA at 45 W for 60 (n = 11) or 90 (12) seconds; 3 ovaries did not undergo MWA and served as histologic controls. Ovaries were histologically evaluated for cell viability. Ovaries without viable cells were categorized as completely ablated. Histologic results were used to identify the optimal MWA protocol for use in the subsequent trial. In the second trial, the ovaries of 9 dogs underwent MWA at 45 W for 90 seconds in situ. Ultrasonographic guidance for MWA was deemed unfeasible after evaluation of 1 ovary. The remaining 17 ovaries underwent MWA with laparoscopic guidance, after which routine laparoscopic oophorectomy was performed. Completeness of ablation was histologically assessed for all ovaries.
2 ovaries were excluded from the trial 1 analysis because of equivocal cell viability. Six of 11 ovaries and 10 of 10 ovaries that underwent MWA for 60 and 90 seconds, respectively, were completely ablated. In trial 2, laparoscopic-guided MWA resulted in complete ablation for 12 of 17 ovaries. Dissection of the ovarian bursa for MWA probe placement facilitated complete ablation.
CONCLUSIONS AND CLINICAL RELEVANCE
Laparoscopic-guided MWA at 45 W for 90 seconds was feasible, safe, and effective for complete ablation of clinically normal ovaries in dogs.